Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | 0.0543 | 0.3434 | 0.3434 | |
Brugia malayi | celfurPC protein | 0.0543 | 0.3434 | 0.3699 |
Loa Loa (eye worm) | hypothetical protein | 0.0699 | 0.4952 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0438 | 0.2409 | 1 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.0438 | 0.2409 | 0.2409 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0248 | 0.0556 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0261 | 0.0689 | 0.1392 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.0492 | 0.2932 | 0.592 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0438 | 0.2409 | 1 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0452 | 0.2543 | 0.2543 |
Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.1218 | 1 | 1 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0699 | 0.4952 | 1 |
Schistosoma mansoni | furin-1 (S08 family) | 0.0296 | 0.1025 | 0.207 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.0438 | 0.2409 | 0.2409 |
Echinococcus granulosus | furin | 0.0699 | 0.4952 | 0.4952 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0452 | 0.2543 | 0.2543 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0699 | 0.4952 | 1 |
Brugia malayi | endoprotease bli-4 precursor | 0.0699 | 0.4952 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Survival (ADMET) | = 53.5 % | Intrinsic cytotoxicity against human K562 cells assessed as cell survival at 10 uM after 24 hrs by MTT assay | ChEMBL. | 25634041 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.